New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
NCT ID NCT07604766
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer growth better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rinatabart sesutecan (Rina-S)
What this could lead to
If it works, this could offer a new treatment option for people with platinum-resistant ovarian cancer, potentially slowing cancer growth better than current chemotherapies.
What could go wrong
This is an early-stage extension study with only 82 participants, so results may not apply to everyone. Rina-S may not prove more effective than existing chemo and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, China
-
Chongqing University Cancer Hospital - Chongqing Cancer Hospital
Chongqing, China
-
Fudan University Shanghai Cancer Hospital
Shanghai, China
-
Fujian Provincial Cancer Hospital
Fujian, China
-
Harbin Medical University Cancer Hospital
Heilongjiang, China
-
Henan Cancer Hospital
Henan, China
-
Hunan Cancer Hospital
Hunan, China
-
Liaoning Cancer Hospital
Liaoning, China
-
Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
Jiangsu, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
-
Peking Union Medical College Hospital
Beijing, China
-
Shandong Cancer Hospital
Shandong, China
-
Shanxi Cancer Hospital
Shanxi, China
-
Sun Yat-Sen Memorial Hospital
Guangdong, China
-
Sun Yat-Sen University Cancer Center
Guangdong, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Shanxi, China
-
The First Hospital of Jilin University
Jilin City, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
-
West China Second University Hospital, Sichuan University
Sichuan, China
-
Zhejiang Cancer Hospital
Zhejiang, China